Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most
widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and …

Nanoparticle-based RNA delivery has shown great progress in recent years with the
approval of two mRNA vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 …

Type 2 diabetes mellitus (T2DM) associated non-alcoholic fatty liver disease (NAFLD) is the
fourth-leading cause of death. Hyperglycemia induces various complications, including …

In vivo interrogation of the function of genes implicated in tumorigenesis is limited by the
need to generate and cross germline mutant mice. Here we describe approaches to model …

Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the
delivery of small interfering RNA (siRNA). Free siRNA molecules suffer from unfavorable …

Though therapeutics based on messenger RNA (mRNA) have broad potential in
applications such as protein replacement therapy, cancer immunotherapy, and genomic …

Spurred by recent progress in medicinal chemistry, numerous lead compounds have sprung
up in the past few years, although the majority are hindered by hydrophobicity, which greatly …

Adding a cationic helper lipid to a lipid nanoparticle (LNP) can increase lung delivery and
decrease liver delivery. However, it remains unclear whether charge-dependent tropism is …

Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …

The CRISPR-Cas system initiated a revolution in genome editing when it was, for the first
time, demonstrated success in the mammalian cells. Today, scientists are able to readily edit …